iFabric receives EPA registration for Cliniweave AV

"The cruise line industry is a clear target market for us with regard to our antiviral technology as onboard outbreaks of infection caused by the Norovirus have been well documented and well publicized in recent years, so we are viewing the receipt of this registration as another important milestone for our company" said Mr. Hylton Karon, President and CEO of iFabric.

"Testing conducted by us at a top North American laboratory, of textiles impregnated with Cliniweave  AV, have shown these textiles to be highly effective against Norovirus and could comprise one of the measures that could be employed by the cruise line industry in order to reduce instances of Norovirus infection" added Mr. Karon.

"In addition, the Center for Disease Control and Prevention, in Atlanta (the "CDC"), reports that there around 20,000,000 cases of Norovirus infection in the United States each year, leading to over 70,000 hospitalizations and 800 deaths which, suggests that there may be a broad market opportunity for solutions geared towards diminishing this epidemic" concluded Mr. Karon.

iFABRIC is a manufacturer, distributor, licensor and licensee of ladies intimate apparel products and accessories as well proprietary chemical compounds that render fabrics intelligent, thereby improving the safety and well-being of the wearer.

iFabric Corp